Skip to content
OpenCapital
Get started

Medpace Holdings, Inc. MEDP Project related reimbursable expenses

Other financials

Income statement

See full
Revenue$706.6M+26.5%
Operating income$141.5M+24.6%
Net income$123.9M+8.1%
EPS (diluted)$4.28+16.6%

Balance sheet

See full
Cash & equivalents$652.7M+47.9%
Total debt$146.1M-2.8%
Total equity$598.3M+0.8%
Total assets$2.1B+12.2%

Cash flow

See full
Operating cash flow$151.8M+20.6%
CapEx$6.8M-31.8%
Free cash flow$145.0M+25.1%

Valuation

See full
Market cap$13.14B+46.8%
Enterprise value$12.64B+45.9%
P/E28.6×+7.0×
P/S4.9×+0.8×

Profitability

See full
Operating margin21%-0.1pp
Net margin17.2%-2.1pp
FCF margin26.5%+1.5pp

Returns & leverage

See full
Return on equity77.3%+11.4pp
Debt / equity0.2×0.0×
Current ratio0.8×+0.1×

Where this comes from

Reported directly by Medpace Holdings, Inc. in its filing.

Tagged under the XBRL concept medp:ProjectRelatedReimbursableExpensesLiabilitiesCurrent.

The official record: Medpace Holdings, Inc.’s 10-Q, filed April 23, 2026, on SEC EDGAR. View the filing →

Ask your AI about Medpace Holdings, Inc.'s project related reimbursable expenses.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Medpace Holdings, Inc.'s project related reimbursable expenses?
Medpace Holdings, Inc. (MEDP) reported project related reimbursable expenses of $332.86M in Q1 2026.
How has Medpace Holdings, Inc.'s project related reimbursable expenses changed year-over-year?
Medpace Holdings, Inc.'s project related reimbursable expenses increased by 50.6% year-over-year, from $221.08M to $332.86M.
What is the long-term trend for Medpace Holdings, Inc.'s project related reimbursable expenses?
Over 4 years (2021 to 2025), Medpace Holdings, Inc.'s project related reimbursable expenses has grown at a 36.2% compound annual growth rate (CAGR), from $91.84M to $316.01M.